Member Info for Abouttime

Shield and Celadon Pharmaceuticals Plc has a good ring to it...

Any thoughts?

Directors buy just come in.

Now come on 6p

Hold till 6.20p

Best time to buy.

According to current analyst consensus, the share price forecast for Shield Therapeutics (STX) is around 16.75 pence, with a range of estimates between 3.50 pence and 30.00 pence, indicating a potential for significant growth based on current price levels.

Key points about the Shield Therapeutics share price forecast:

Average analyst target: 16.75 pence

High estimate: 30.00 pence

Low estimate: 3.50 pence

Best time to buy. My opinion. 33k investment

Shield Interim Chief Executive Anders Lundstrom said: "It has been another successful quarter for Shield as we work towards becoming CASH FLOW POSITIVE by the end of financial year 2025. We continue to see increased demand for ACCRUFeR in the US and across all our territories.

"Net sales, total prescriptions and the net selling price of ACCRUFeR are all showing positive trends, and with a strengthened balance sheet and tight control of our cost base we will continue to build momentum behind ACCRUFeR and make the steps required to transition to cash flow positive by the end of 2025."

So the big question is when will they announce that their bebt free. One month or two. Then this share will fly...

Topped up 5k

Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) has reported a notable step forward for its helium project in Colorado, where the authorities have now approved a five well development plan.

The Colorado Energy and Carbon Management Commission (ECMC) has approved five new development wells at the Galactica-Pegasus helium project, the company told investors.

Located near the proposed plant site, these wells are expected to form part of the initial gas-gathering system for helium production, it noted

UK

proactive logo

Shield Therapeutics shares up 8% after phase III success

Published: 08:23 25 Sep 2024 BST

Written by: Ian Lyall

About this content

View

Shield Therapeutics PLC

AIM:STX

OTCQX:SHIEF

Shield Therapeutics PLC -

Shield Therapeutics PLC's (AIM:STX, OTCQX:SHIEF) share price rose 8% following the announcement of successful phase III trial results for its iron deficiency treatment, Accrufer, which could pave the way for its use in children.

The UK-based speciality pharmaceutical company reported that the oral drug, known scientifically as ferric maltol, showed significant efficacy and safety in paediatric patients aged 2 to 17, with an average haemoglobin increase of 1.25 g/dL over 12 weeks.

The trial, which also demonstrated higher results in infants, marks the completion of Shield’s development programme.

The company plans to seek approval for use in children older than one month in Europe and the US by mid-2025.

Shield also expects a €1 million milestone payment from partner Norgine, contingent upon European Medicines Agency approval.

City broker Peel Hunt said: "We believe there is little doubt about the unmet need for Accrufer, with 20 million patients in the US alone having anaemia.

"Market traction is now very much a function of continued focus and investment in marketing and commercialisation."

Share price rose 8% following the announcement of successful phase III trial results for its iron deficiency treatment, Accrufer, which could pave the way for its use in children.

The UK-based speciality pharmaceutical company reported that the oral drug, known scientifically as ferric maltol, showed significant efficacy and safety in paediatric patients aged 2 to 17, with an average haemoglobin increase of 1.25 g/dL over 12 weeks.

Buys coming in at a cheap price

Interim CEO Anders Lundstrom and CFO Santosh Shanbhag take Proactive's Stephen Gunnion through the company's impressive growth in the iron deficiency market. They discussed the key highlights from the first half of the year, including a 3.5x increase in Accrufer revenues, bringing in $11 million in total net revenue. Shanbhag emphasised this growth was driven by both increased prescriptions and improved pricing strategies.

Lundstrom provided insights into Shield Therapeutics' broader market strategy, focusing on their collaboration with Viatris and global partners to expand Accrufer's reach. He highlighted recent milestones such as Health Canada's approval of Accrufer, marking a significant step in the company's global expansion.

Shanbhag further detailed Shield's financial positioning, including maintaining $8.1 million in cash and strategic financing moves to support ongoing growth. As Shield Therapeutics continues to penetrate the US market and explore new opportunities worldwide, investors should stay tuned for updates on their strategic initiatives and upcoming pediatric study results.

Https://www.proactiveinvestors.co.uk/LON:STX/Shield-Therapeutics-PLC/

Hailed another 'strong period of growth' as it delivered a more than three-fold increase in revenue in the first half based on the growing uptake of its anaemia drug ACCRUFeR.

Sales were $12.1 million, with its oral ferric maltol treatment accounting for $11 million. Total prescriptions were 65,200 at a quarterly growth rate of 25%, while the product's price also increased.

It exited the period with $8.1 million in the bank, which will be supplemented by $5.7 million from a milestone monetisation agreement inked after June 30. Shield posted an operating loss of $15.5 million, driven primarily by the expansion of the US field force.

"We continue to focus on building momentum through creating greater awareness of ACCRUFeR® among healthcare professionals in the US as well as expanding our geographic reach with our international partners," said Anders Lundstrom, interim CEO.

Looking ahead, Kye Pharmaceuticals, Shield’s Canadian partner, is preparing for a late 2024 product launch. As part of their collaboration, Shield will receive a £250,000 milestone payment, along with additional revenue-based payments and double-digit royalties on net sales during the agreement's term.

Further developments include Korea Pharma’s submission of a new drug application for ACCRUFeR in South Korea following a successful pharmacokinetic study, and ASK Pharma’s ongoing phase III trial in China, expected to complete enrollment by late 2024.

Additionally, Shield is progressing a phase III pediatric study comparing ferric maltol with ferrous sulphate in children with iron deficiency anaemia, with results anticipated later this year. This study is the final phase of the company's pediatric development programme for regulatory approval.

8 million profit

Roll on tomorrow.

Keras Resources plc (AIM: KRS) ("Keras") is pleased to announce the commencement of commercial production of PhoSul® granules at its Integrated Delta Processing facility, Utah. Several upgrades and optimisations were implemented progressing from hot commissioning to commercial production, with consistent production now having been achieved by the operational team from contractor Burningham Enterprises Group operating on a single shift basis to maintain and improve upon nameplate saleable product output of 5 tons per hour. The timely achievement of this milestone was made materially smoother with on-site input from the Company's joint venture ("JV") partners PhoSul LLC, which has saved Keras both time and cost.

The JV will spend the coming months operating on a single shift basis ironing out early production improvements, progressing to double shift operations during the fourth quarter of 2024 and progressively to continuous operations during the first quarter of 2025.

Per previous announcements, PhoSul®'s formulation has been specifically developed to improve Phosphorous ("P2O5") availability to crops, where results from field tests have demonstrated significant yield and quality improvements over competitor rock phosphate sources. With current traditional phosphate fertilizer production and use under increased environmental pressure, PhoSul® further helps to solve Phosphorous run-off and water resource contamination, a key component of the Company's organic identity.

Preparations for the 2024 summer mining season have commenced, during which the Company plans to produce between 8,000 and 10,000 tons dictated by demand during the back end of summer and early fall. 100% owned Falcon Isle Resources ("FIR") will sell rock phosphate to the JV, building up to steady-state sales of approximately 10,500 tons per annum, in addition to internal sales of approximately 6,500 tons per annum.

Graham Stacey, CEO of Keras, commented, "It is naturally an exciting time for us to be building a PhoSul® stockpile at our Delta Facility. Organic granulation requires a very specific formula and the blending of the PhoSul® ingredients in the design ratio, supplemented with moisture, an organic binder and a dust control agent in the overall product blend has been a challenging process which we will continue to optimise with strong support from our PhoSul LLC JV colleagues. An important part of our transition to sales will include moisture and hardness testing as well as 240 size guide number ("SGN") analysis on an ongoing basis. Our intention is to produce 240SGN product in bulk in the short-to medium-term, with the option to produce 1 ton bags should demand dictate.

"The move to Delta has been a significant shift in our operating model, we look forward to settling into our new facility, optimising operations and growing our sales without the distractions we've experienced to date, and delivering profitability to our sharehol